US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults
Date postedJuly 13, 2023
EAST HANOVER, N.J., July 10, 2023 / PRNewswire / — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy1. This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a first cardiovascular event2.